Radius publishes data on its research in breast cancer in a variety of scientific or medical journals. Below are select articles relating to the development of our clinical pipeline.
EMERALD: Phase III Trial of Elacestrant (RAD1901) vs Endocrine Therapy for Previously Treated ER+ Advanced Breast Cancer.
Future Oncol. 2019; August 20 [Epub ahead of print]. Bardia A, Aftimos P, Bihani T, Anderson-Villaluz AT, Jung J, Conlan MG, Kaklamani VG.
Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor-Positive Breast Cancer Models with a Distinct Mechanism of Action.
Clin Cancer Res. 2017;23(24):17608-17620. Yu Z, He S, Wang D, Patel HK, Miller CP, Brown JL, Hattersley G, Saeh JC.
Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-Derived Xenograft Models.
Clin Cancer Res. 2017;23(16):4793-4804. Bihani T, Patel HK, Arlt H, Tao N, Jiang H, Brown JL, Purandare DM, Hattersley G, Garner F.
RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models.
Anticancer Drugs. 2015;26(9):948-56. Garner F, Shomali M, Paquin D, Lyttle CR, Hattersley G.